AMAG Pharmaceuticals, Inc. (AMAG) Announces Positive Preliminary Results From an Extension Study Evaluating the Safety and Efficacy of Repeat Dosing With Ferumoxytol in Patients With Persistent or Recurring Iron Deficiency Anemia, Regardless of the Underlying Cause
3/15/2013 10:21:25 AM
LEXINGTON, Mass.--(BUSINESS WIRE)--AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced positive preliminary data from the IDA-303 study. IDA-303 is a single arm, open-label extension study that evaluated the safety and efficacy of repeat dosing with ferumoxytol in patients with persistent or recurring iron deficiency anemia (IDA) regardless of the underlying cause and a history of unsatisfactory oral iron therapy or in whom oral iron could not be used. Patients were eligible to enroll in the IDA-303 extension study after they completed IDA-301, which was a double-blind, placebo-controlled trial that randomized patients to receive either a one gram intravenous course of ferumoxytol or placebo, the results of which were previously reported by the company and presented at the American Society of Hematology annual meeting in December 2012.